JP2017538769A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538769A5 JP2017538769A5 JP2017533416A JP2017533416A JP2017538769A5 JP 2017538769 A5 JP2017538769 A5 JP 2017538769A5 JP 2017533416 A JP2017533416 A JP 2017533416A JP 2017533416 A JP2017533416 A JP 2017533416A JP 2017538769 A5 JP2017538769 A5 JP 2017538769A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- salt
- pharmaceutically acceptable
- solvate
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 22
- 239000012453 solvate Substances 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- QEUAUMWHNLVMDZ-HXUWFJFHSA-N 6-(5-fluoroquinolin-7-yl)-3-[(3R)-3-methyl-2-oxopiperidin-3-yl]-1H-pyridin-2-one Chemical compound FC1=C2C=CC=NC2=CC(=C1)C1=CC=C(C(N1)=O)[C@@]1(C(NCCC1)=O)C QEUAUMWHNLVMDZ-HXUWFJFHSA-N 0.000 claims 2
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 claims 1
- OJVNYQOKTZLPPX-OAQYLSRUSA-N 3-[(3R)-3-methyl-2-oxopiperidin-3-yl]-6-(5-methylquinolin-3-yl)-1H-pyridin-2-one Chemical compound C[C@]1(C(NCCC1)=O)C=1C(NC(=CC=1)C=1C=NC2=CC=CC(=C2C=1)C)=O OJVNYQOKTZLPPX-OAQYLSRUSA-N 0.000 claims 1
- URFCQPHIMBZYON-OAQYLSRUSA-N 3-[(3R)-3-methyl-2-oxopiperidin-3-yl]-6-(5-methylquinolin-7-yl)-1H-pyridin-2-one Chemical compound C[C@]1(C(NCCC1)=O)C=1C(NC(=CC=1)C1=CC(=C2C=CC=NC2=C1)C)=O URFCQPHIMBZYON-OAQYLSRUSA-N 0.000 claims 1
- NYMPHOZUBJYHBQ-HXUWFJFHSA-N 3-[(3R)-3-methyl-2-oxopyrrolidin-3-yl]-6-(5-methylquinolin-3-yl)-1H-pyridin-2-one Chemical compound C[C@]1(C(NCC1)=O)C=1C(NC(=CC=1)C=1C=NC2=CC=CC(=C2C=1)C)=O NYMPHOZUBJYHBQ-HXUWFJFHSA-N 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- ALGSMAYBBGCDSR-HXUWFJFHSA-N 6-(5-chloroquinolin-7-yl)-3-[(3R)-3-methyl-2-oxopiperidin-3-yl]-1H-pyridin-2-one Chemical compound ClC1=C2C=CC=NC2=CC(=C1)C1=CC=C(C(N1)=O)[C@@]1(C(NCCC1)=O)C ALGSMAYBBGCDSR-HXUWFJFHSA-N 0.000 claims 1
- JXKXDDNPECXKSM-HSZRJFAPSA-N 6-(5-cyclopropylquinolin-7-yl)-3-[(3R)-3-methyl-2-oxopiperidin-3-yl]-1H-pyridin-2-one Chemical compound C1(CC1)C1=C2C=CC=NC2=CC(=C1)C1=CC=C(C(N1)=O)[C@@]1(C(NCCC1)=O)C JXKXDDNPECXKSM-HSZRJFAPSA-N 0.000 claims 1
- KPRFPENKXRBQRF-JOCHJYFZSA-N 6-(5-ethylquinolin-7-yl)-3-[(3R)-3-methyl-2-oxopiperidin-3-yl]-1H-pyridin-2-one Chemical compound C(C)C1=C2C=CC=NC2=CC(=C1)C1=CC=C(C(N1)=O)[C@@]1(C(NCCC1)=O)C KPRFPENKXRBQRF-JOCHJYFZSA-N 0.000 claims 1
- ICRVRXNPWUOCMP-IVAFLUGOSA-N CCc1cc(cc2ncccc12)C1=NC(=O)C(C=C1)[C@@]1(C)CCCNC1=O Chemical compound CCc1cc(cc2ncccc12)C1=NC(=O)C(C=C1)[C@@]1(C)CCCNC1=O ICRVRXNPWUOCMP-IVAFLUGOSA-N 0.000 claims 1
- ZTBLZTHRYZXYNZ-WBPHRXDCSA-N C[C@@]1(CCCNC1=O)C1C=CC(=NC1=O)c1cc(C2CC2)c2cccnc2c1 Chemical compound C[C@@]1(CCCNC1=O)C1C=CC(=NC1=O)c1cc(C2CC2)c2cccnc2c1 ZTBLZTHRYZXYNZ-WBPHRXDCSA-N 0.000 claims 1
- SGMZEERLWJABMZ-YBMSBYLISA-N C[C@@]1(CCCNC1=O)C1C=CC(=NC1=O)c1cc(Cl)c2cccnc2c1 Chemical compound C[C@@]1(CCCNC1=O)C1C=CC(=NC1=O)c1cc(Cl)c2cccnc2c1 SGMZEERLWJABMZ-YBMSBYLISA-N 0.000 claims 1
- SSQLJNRCSCKPFA-MYKUNDNFSA-N Cc1cc(cc2ncccc12)C1CCC(C(=O)N1)[C@@]1(C)CCCNC1=O Chemical compound Cc1cc(cc2ncccc12)C1CCC(C(=O)N1)[C@@]1(C)CCCNC1=O SSQLJNRCSCKPFA-MYKUNDNFSA-N 0.000 claims 1
- ZUCVEFCHDRKBHT-MYKUNDNFSA-N Cc1cccc2ncc(cc12)C1CCC(C(=O)N1)[C@@]1(C)CCCNC1=O Chemical compound Cc1cccc2ncc(cc12)C1CCC(C(=O)N1)[C@@]1(C)CCCNC1=O ZUCVEFCHDRKBHT-MYKUNDNFSA-N 0.000 claims 1
- RXTUYFXTGPOYIV-ALLBUHFWSA-N Cc1cccc2ncc(cc12)C1CCC(C(=O)N1)[C@@]1(C)CCNC1=O Chemical compound Cc1cccc2ncc(cc12)C1CCC(C(=O)N1)[C@@]1(C)CCNC1=O RXTUYFXTGPOYIV-ALLBUHFWSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 150000004682 monohydrates Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000007614 solvation Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462095337P | 2014-12-22 | 2014-12-22 | |
| US62/095,337 | 2014-12-22 | ||
| US201562259528P | 2015-11-24 | 2015-11-24 | |
| US62/259,528 | 2015-11-24 | ||
| PCT/IB2015/059548 WO2016103097A1 (en) | 2014-12-22 | 2015-12-11 | Antagonists of prostaglandin ep3 receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017538769A JP2017538769A (ja) | 2017-12-28 |
| JP2017538769A5 true JP2017538769A5 (https=) | 2019-01-24 |
Family
ID=55077554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533416A Withdrawn JP2017538769A (ja) | 2014-12-22 | 2015-12-11 | プロスタグランジンｅｐ３受容体の拮抗薬 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9738626B2 (https=) |
| EP (1) | EP3237401B1 (https=) |
| JP (1) | JP2017538769A (https=) |
| CA (1) | CA2915470A1 (https=) |
| TW (1) | TW201632513A (https=) |
| UY (1) | UY36455A (https=) |
| WO (1) | WO2016103097A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10336701B2 (en) | 2017-08-10 | 2019-07-02 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists |
| US10399944B2 (en) | 2017-08-10 | 2019-09-03 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists |
| US10590083B2 (en) | 2017-08-10 | 2020-03-17 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists |
| CR20200554A (es) | 2018-05-17 | 2021-01-12 | Bayer Ag | Derivados sustituidos de la carboxamida dihidropirazolo pirazina |
| WO2021094208A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted imidazo pyrimidine ep3 antagonists |
| WO2021094209A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
| WO2021094210A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
| IL307374A (en) | 2021-04-07 | 2023-11-01 | Hadasit Med Res Service | EP3 antagonists for the treatment of diabetes |
| CN116106398A (zh) * | 2022-08-03 | 2023-05-12 | 南方医科大学珠江医院 | 用于诊断ckd的标志物 |
| KR20260011665A (ko) * | 2023-03-13 | 2026-01-23 | 오노 야꾸힝 고교 가부시키가이샤 | 삼환성 화합물 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4219483A (en) | 1978-09-11 | 1980-08-26 | Pfizer Inc. | 4-Pyrone prostaglandin antagonists |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| WO2000001389A1 (en) | 1998-07-06 | 2000-01-13 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| IL157253A0 (en) | 2001-02-28 | 2004-02-19 | Merck & Co Inc | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| NZ534582A (en) | 2002-02-27 | 2006-03-31 | Pfizer Prod Inc | ACC inhibitors |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| KR100869616B1 (ko) | 2004-05-12 | 2008-11-21 | 화이자 프로덕츠 인코포레이티드 | 프롤린 유도체 및 그의 다이펩티딜 펩티다제－ｉｖ저해제로서의 용도 |
| UA84208C2 (en) | 2004-05-25 | 2008-09-25 | Пфайзер Продактс Инк. | Tetraazabenzo(e)azulene derivatives and analogs thereof |
| JP5063348B2 (ja) | 2004-08-26 | 2012-10-31 | アクテリオン ファーマシューティカルズ リミテッド | ２−スルファニル−ベンゾイミダゾール−１−イル−酢酸誘導体 |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| WO2007027630A2 (en) | 2005-08-30 | 2007-03-08 | Smithkline Beecham Corporation | Genes associated with type ii diabetes mellitus |
| JP5190448B2 (ja) | 2006-04-20 | 2013-04-24 | ファイザー・プロダクツ・インク | グルコキナーゼ仲介疾患を予防および治療するための縮合フェニルアミド複素環化合物 |
| EA200900613A1 (ru) | 2006-11-29 | 2009-10-30 | Пфайзер Продактс Инк. | Спирокетоновые ингибиторы ацетил-коа-карбоксилаз |
| WO2008139287A1 (en) | 2007-05-10 | 2008-11-20 | Pfizer Limited | Azetidine derivatives and their use as prostaglandin e2 antagonists |
| PT2152712E (pt) | 2007-05-11 | 2012-02-29 | Pfizer | Compostos amino-heterocíclicos |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| US20110009443A1 (en) | 2008-05-28 | 2011-01-13 | Kevin Daniel Freeman-Cook | Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors |
| WO2009144554A1 (en) | 2008-05-28 | 2009-12-03 | Pfizer, Inc. | Pyrazolospiroketone acetyl-c0a carboxylase inhibitors |
| EP2318370A1 (en) | 2008-07-29 | 2011-05-11 | Pfizer Inc. | Fluorinated heteroaryls |
| MY155418A (en) | 2008-08-28 | 2015-10-15 | Pfizer | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| WO2010086820A1 (en) | 2009-02-02 | 2010-08-05 | Pfizer Inc. | 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof |
| MY151246A (en) | 2009-03-11 | 2014-04-30 | Pfizer | Benzofuranyl derivatives |
| US20110319379A1 (en) | 2009-03-11 | 2011-12-29 | Corbett Jeffrey W | Substituted Indazole Amides And Their Use As Glucokinase Activators |
| WO2010106457A2 (en) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
| WO2010128414A1 (en) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Gpr 119 modulators |
| CA2759843A1 (en) | 2009-05-08 | 2010-11-10 | Pfizer Inc. | Gpr 119 modulators |
| NZ596467A (en) | 2009-06-05 | 2014-01-31 | Pfizer | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
| KR101548443B1 (ko) | 2011-02-23 | 2015-08-28 | 화이자 인코포레이티드 | 신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진 |
| SG195085A1 (en) | 2011-06-07 | 2013-12-30 | Pfizer | Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors |
| ES2665153T3 (es) | 2013-10-09 | 2018-04-24 | Pfizer Inc. | Antagonistas del receptor EP3 de prostaglandina |
-
2015
- 2015-12-11 WO PCT/IB2015/059548 patent/WO2016103097A1/en not_active Ceased
- 2015-12-11 EP EP15821169.8A patent/EP3237401B1/en not_active Not-in-force
- 2015-12-11 JP JP2017533416A patent/JP2017538769A/ja not_active Withdrawn
- 2015-12-16 US US14/970,930 patent/US9738626B2/en not_active Expired - Fee Related
- 2015-12-17 TW TW104142513A patent/TW201632513A/zh unknown
- 2015-12-17 CA CA2915470A patent/CA2915470A1/en not_active Abandoned
- 2015-12-18 UY UY0001036455A patent/UY36455A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538769A5 (https=) | ||
| HRP20200538T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| JP2017504635A5 (https=) | ||
| JP2013523802A5 (https=) | ||
| JP2016521710A5 (https=) | ||
| JP2015522650A5 (https=) | ||
| JP2013542261A5 (https=) | ||
| JP2016513660A5 (https=) | ||
| JP2017509586A5 (https=) | ||
| JP2013129675A5 (https=) | ||
| MY187617A (en) | Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceutical applications thereof | |
| JP2016530259A5 (https=) | ||
| JP2017517512A5 (https=) | ||
| JP2019501125A5 (https=) | ||
| JP2016507581A5 (https=) | ||
| JP2016518328A5 (https=) | ||
| WO2016012965A3 (en) | Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof | |
| JP2017526701A5 (https=) | ||
| JP2016512520A5 (https=) | ||
| JP2015512883A5 (https=) | ||
| JP2017537937A5 (https=) | ||
| JP2014502988A5 (https=) | ||
| JP2017506666A5 (https=) | ||
| HRP20192279T1 (hr) | Novi spojevi imidazopiridazina i njihova uporaba | |
| JP2016528273A5 (https=) |